Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026Clinical Trial Application (CTA) ...
Insurancenewsnet.com

Tangram Insurance Services and Markel Announce Partnership to Provide Excess Liability Capacity For Tangram’s Propane & Fuel Program

PETALUMA, Calif., Oct. 14, 2020 /PRNewswire/ -- Tangram Insurance Services, Inc. ("Tangram"), a Managing General Agency, and Markel Corporation on behalf of its affiliated insurance companies ("Markel ...

Tangram Therapeutics PLC: Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram's GalOmic RNAi ...